Free Trial

One Wealth Advisors LLC Invests $295,000 in Cigna Group (NYSE:CI)

Cigna Group logo with Medical background

One Wealth Advisors LLC acquired a new position in shares of Cigna Group (NYSE:CI - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 896 shares of the health services provider's stock, valued at approximately $295,000.

Other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new position in Cigna Group during the fourth quarter valued at approximately $867,785,000. T. Rowe Price Investment Management Inc. acquired a new position in Cigna Group during the fourth quarter valued at approximately $724,517,000. GAMMA Investing LLC raised its position in Cigna Group by 58,799.0% during the first quarter. GAMMA Investing LLC now owns 1,774,626 shares of the health services provider's stock valued at $583,852,000 after purchasing an additional 1,771,613 shares in the last quarter. Two Sigma Advisers LP grew its position in Cigna Group by 278.0% in the fourth quarter. Two Sigma Advisers LP now owns 816,200 shares of the health services provider's stock valued at $225,385,000 after acquiring an additional 600,300 shares during the last quarter. Finally, Voloridge Investment Management LLC grew its position in Cigna Group by 400.9% in the fourth quarter. Voloridge Investment Management LLC now owns 643,253 shares of the health services provider's stock valued at $177,628,000 after acquiring an additional 514,841 shares during the last quarter. Institutional investors own 86.99% of the company's stock.

Cigna Group Stock Performance

NYSE:CI traded up $2.43 during trading on Friday, reaching $296.36. The company's stock had a trading volume of 1,325,699 shares, compared to its average volume of 1,724,874. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.72 and a current ratio of 0.72. The firm has a market cap of $79.17 billion, a price-to-earnings ratio of 16.41, a price-to-earnings-growth ratio of 0.89 and a beta of 0.44. The firm has a 50 day moving average of $312.53 and a 200-day moving average of $311.87. Cigna Group has a 12 month low of $262.03 and a 12 month high of $370.83.

Cigna Group (NYSE:CI - Get Free Report) last posted its quarterly earnings results on Friday, May 2nd. The health services provider reported $6.74 EPS for the quarter, topping analysts' consensus estimates of $6.35 by $0.39. The company had revenue of $65.45 billion for the quarter, compared to analysts' expectations of $60.39 billion. Cigna Group had a net margin of 1.97% and a return on equity of 18.63%. Cigna Group's revenue was up 14.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.47 EPS. Research analysts expect that Cigna Group will post 29.77 EPS for the current fiscal year.

Cigna Group Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 18th. Shareholders of record on Thursday, September 4th will be issued a dividend of $1.51 per share. The ex-dividend date is Thursday, September 4th. This represents a $6.04 dividend on an annualized basis and a yield of 2.04%. Cigna Group's payout ratio is 33.44%.

Analysts Set New Price Targets

A number of research firms have issued reports on CI. Piper Sandler lifted their target price on Cigna Group from $348.00 to $374.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Mizuho upped their price target on shares of Cigna Group from $360.00 to $384.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Truist Financial upped their price target on shares of Cigna Group from $385.00 to $405.00 and gave the stock a "buy" rating in a report on Monday, May 12th. Robert W. Baird lowered their price target on shares of Cigna Group from $388.00 to $362.00 and set an "outperform" rating for the company in a report on Tuesday, April 15th. Finally, Guggenheim reiterated a "buy" rating and set a $388.00 price target on shares of Cigna Group in a report on Friday, May 23rd. Two investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $380.39.

Get Our Latest Stock Report on Cigna Group

About Cigna Group

(Free Report)

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.

Recommended Stories

Institutional Ownership by Quarter for Cigna Group (NYSE:CI)

Should You Invest $1,000 in Cigna Group Right Now?

Before you consider Cigna Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cigna Group wasn't on the list.

While Cigna Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines